GET DAILY SIGNALSFortress Biotech (FBIO) Stock Drops -11.5% in 30 Days Following Analyst Downgrade
Key Takeaways
- Fortress Biotech (FBIO) shares fell about 11.5% over the trailing 30 days, declining from roughly $2.09 to $1.85 as of the most recent close.
- The decline extended a longer slide, with the stock down roughly 31% over the last quarter and trading near the low end of its 52-week range of $1.79 to $4.53.
- An analyst ratings downgrade in late October coincided with renewed selling pressure in the small-cap biopharmaceutical name.
- Fundamentals remained comparatively stable, as the company's most recent quarter showed 23% year-over-year revenue growth and a first positive-EBITDA period.
- The upcoming third-quarter earnings report and continued Emrosi prescription momentum are among the most closely watched near-term catalysts.
- For additional context on valuation and expectations, investors can explore the company's Price Targets, Earnings, and Forecast pages.
- Traders interested in automated strategies for this name can also review Trending AI Robots.
Fortress Biotech (FBIO) Company Overview and Market Position
Fortress Biotech, Inc. is a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical and biotechnology assets, often through a network of majority-owned and partner companies. The company markets eight prescription products and supports more than 20 development programs spanning oncology, dermatology, and rare diseases.
Its commercial portfolio is anchored by dermatology products such as Emrosi (rosacea), Qbrexza (axillary hyperhidrosis), Amzeeq and Zilxi (acne and rosacea), and Accutane. Its subsidiary Journey Medical drives much of the commercial dermatology franchise. Later-stage pipeline candidates include CUTX-101 for Menkes disease, the Triplex cytomegalovirus (CMV) vaccine, and CAEL-101 for AL amyloidosis. Investors follow FBIO for the combination of growing commercial product revenue and the optionality embedded in its partnered development programs. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Fortress Biotech (FBIO) Stock Price Performance: Last 30 Days vs. Quarter
Over the most recent 30-day period, FBIO shares moved from a closing price of approximately $2.09 in early October to $1.85, representing a decline of roughly 11.5%. The stock traded in a generally downward channel during this stretch, with an intraday low near $1.79 in early November placing it at the bottom of its 52-week range.
The quarterly picture is steeper. From a level of about $2.67 in early August, the shares have fallen to $1.85, a decline of approximately 31%. This indicates that the recent 30-day weakness is part of a broader multi-month downtrend rather than an isolated event, even as the company's underlying commercial results continued to improve.
What Drove FBIO Stock Price in the Last 30 Days
No single company-specific event fully explains the decline, but several factors contributed to the downward pressure. In late October, a third-party ratings firm downgraded its outlook on FBIO to a sell rating, which coincided with additional selling in the thinly traded, small-cap name. The stock also carried the weight of a sector backdrop in which speculative and pre-commercial biotech equities faced renewed risk-off sentiment.
The move occurred despite comparatively stable fundamentals. The company's prior quarterly report, released in August, showed total revenue of $18.5 million, up 23% year over year, driven by Emrosi, and a narrowed GAAP net loss alongside positive non-GAAP EBITDA. With no major negative product or pipeline disclosures reported during the 30-day window, the price action appeared driven more by ratings, sentiment, and technical selling than by a deterioration in the operating business. When I looked at recent signals, Tickeron’s AI Daily Buy/Sell Signals helped put the price action in context.
What Drove FBIO Stock Performance Over the Last Quarter
The broader quarterly decline reflects a longer unwind after a strong first half. FBIO reached a 52-week high of $4.53 earlier in the period and has since retreated as investors reassessed the valuation of a small-cap company that is transitioning toward commercial profitability but remains dependent on the ramp of its flagship dermatology product.
Company-specific progress was positive during the quarter: Emrosi prescriptions grew about 20% sequentially, unique prescribers surpassed 4,500, a major national health plan added the product to its formulary, and Eurax cream was launched as an additional revenue stream. However, the stock's prior gains and a low float contributed to volatility, and profit-taking, combined with cautious ratings commentary, weighed on the share price even as operational metrics improved.
FBIO Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the most important near-term catalyst is the company's third-quarter earnings report, estimated for mid-November, with consensus expectations pointing to continued year-over-year revenue growth driven by Emrosi. Investors will watch prescription trends, average selling price, payer coverage expansion, and whether the company sustains positive EBITDA.
Additional factors include the ramp of Eurax cream, potential out-licensing or partnership developments for Emrosi in international markets, and progress on later-stage pipeline programs. Macro risks such as interest-rate expectations, small-cap biotech fund flows, and broader market risk appetite could also influence sentiment. These items provide a factual framework for monitoring the stock, though no forward-looking outcome should be treated as a prediction. I’m watching this closely as the earnings date approaches.
Exploring Automated Strategies for FBIO
In my own analysis, I often review Tickeron’s AI Trading Bots to see how different automated approaches might align with names like this one amid volatility.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
FBIO in upward trend: price may jump up because it broke its lower Bollinger Band on November 05, 2026
FBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 35 cases where FBIO's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where FBIO's RSI Indicator exited the oversold zone, 32 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 68 cases where FBIO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for FBIO just turned positive on October 20, 2026. Looking at past instances where FBIO's MACD turned positive, the stock continued to rise in 42 of 53 cases over the following month. The odds of a continued upward trend are 79%.
Following a +2.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where FBIO advanced for three days, in 204 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FBIO as a result. In 72 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for FBIO entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.376) is normal, around the industry mean (3.498). P/E Ratio (0.569) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.145) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. FBIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel immunotherapy biologic agents
Industry Biotechnology
Advertisement